News & Media > Letter from Janssen to BHIVA re: Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
Monday 16 March 2020
Download the letter received from Janssen Pharmaceutical Companies of Johnson & Johnson
For further information, please contact Jo Josh on +44 (0) 7787 530922 or [email protected]